These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36193738)

  • 21. Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
    Dijk W; Cariou B
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():39-51. PubMed ID: 31002456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Meroni M; Longo M; Lombardi R; Paolini E; Macchi C; Corsini A; Sirtori CR; Fracanzani AL; Ruscica M; Dongiovanni P
    Hepatol Commun; 2022 Mar; 6(3):535-549. PubMed ID: 34677008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study.
    Peng J; Liu MM; Jin JL; Cao YX; Guo YL; Wu NQ; Zhu CG; Dong Q; Sun J; Xu RX; Li JJ
    Lipids Health Dis; 2022 Jan; 21(1):3. PubMed ID: 34996457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas.
    Mbikay M; Mayne J; Sirois F; Fedoryak O; Raymond A; Noad J; Chrétien M
    Mol Nutr Food Res; 2018 May; 62(9):e1700729. PubMed ID: 29396908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PCSK9 and lipid lowering drugs.
    Guo YL; Zhang W; Li JJ
    Clin Chim Acta; 2014 Nov; 437():66-71. PubMed ID: 25036764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing
    Lebeau PF; Byun JH; Platko K; MacDonald ME; Poon SV; Faiyaz M; Seidah NG; Austin RC
    J Biol Chem; 2019 Jun; 294(23):9037-9047. PubMed ID: 31004037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD.
    Vilar-Gomez E; Gawrieh S; Liang T; McIntyre AD; Hegele RA; Chalasani N
    J Clin Lipidol; 2021; 15(2):275-291. PubMed ID: 33454241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
    Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
    [No Abstract]   [Full Text] [Related]  

  • 30. A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH).
    Sekhon AK; Gollapalli A; Kaur D; Janssen B; Stevens ML; Valerio F; Sierra-Hoffman MA
    Am J Case Rep; 2021 Nov; 22():e932961. PubMed ID: 34826302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a role of lipid-lowering therapies in the management of fatty liver disease?
    Tzanaki I; Agouridis AP; Kostapanos MS
    World J Hepatol; 2022 Jan; 14(1):119-139. PubMed ID: 35126843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
    Di Filippo M; Vokaer B; Seidah NG
    J Clin Lipidol; 2017; 11(4):1101-1105. PubMed ID: 28711549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia.
    Cansby E; Magnusson E; Nuñez-Durán E; Amrutkar M; Pedrelli M; Parini P; Hoffmann J; Ståhlman M; Howell BW; Marschall HU; Borén J; Mahlapuu M
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1723-1737. PubMed ID: 29930001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver.
    Shafiq M; Walmann T; Nutalapati V; Gibson C; Zafar Y
    World J Hepatol; 2020 Dec; 12(12):1258-1266. PubMed ID: 33442452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.
    Shahreyar M; Salem SA; Nayyar M; George LK; Garg N; Koshy SKG
    J Am Board Fam Med; 2018; 31(4):628-634. PubMed ID: 29986989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances.
    Atar D; Langslet G; Tonstad S
    Kardiol Pol; 2022; 80(7-8):741-749. PubMed ID: 35521719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?
    Kashyap ML; Ganji S; Nakra NK; Kamanna VS
    J Clin Lipidol; 2019; 13(6):873-879. PubMed ID: 31706905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.
    Mu G; Xiang Q; Zhou S; Liu Z; Qi L; Jiang J; Gong Y; Xie Q; Wang Z; Zhang H; Huo Y; Cui Y
    Adv Ther; 2020 Apr; 37(4):1496-1521. PubMed ID: 32108309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.